Cochrane · systematic review · CD012537
Non‐steroidal anti‐inflammatory drugs (NSAIDs) for chronic non‐cancer pain in children and adolescents
Eccleston, C, Cooper, TE, Fisher, E, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Pain, Palliative and Supportive CareAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
12
No studies
6
Included studies
NR
No studies 6 · 33.3%Ungraded 0 · 0%Very low 8 · 44.4%Low 4 · 22.2%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Meloxicam compared with naproxen for chronic non‐cancer pain
Population: children and adolescents with chronic non‐cancer pain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participant‐reported pain relief of 30% or greater Meloxicam vs naproxen | no estimate extracted | 1 study · 225 participants | Low Downgraded: risk of bias, imprecision |
Participant‐reported pain relief of 50% or greater Meloxicam vs naproxen | no estimate extracted | 1 study · 225 participants | Low Downgraded: risk of bias, imprecision |
Patient Global Impression of Change much or very much improved Meloxicam vs naproxen | no estimate extracted | NR | No studies |
Any adverse event Meloxicam vs naproxen | no estimate extracted | 1 study · 225 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse event Meloxicam vs naproxen | no estimate extracted | 1 study · 225 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Meloxicam vs naproxen | no estimate extracted | 1 study · 225 participants | Very low Downgraded: risk of bias, imprecision |
Celecoxib compared with naproxen for chronic non‐cancer pain
Population: children and adolescents with chronic non‐cancer pain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participant‐reported pain relief of 30% or greater Celecoxib vs naproxen | no estimate extracted | 1 study · 242 participants | Low Downgraded: risk of bias, imprecision |
Participant‐reported pain relief of 50% or greater Celecoxib vs naproxen | no estimate extracted | NR | No studies |
Patient Global Impression of Change much or very much improved Celecoxib vs naproxen | no estimate extracted | NR | No studies |
Any adverse event Celecoxib vs naproxen | no estimate extracted | NR | No studies |
Serious adverse event Celecoxib vs naproxen | no estimate extracted | 1 study · 242 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Celecoxib vs naproxen | no estimate extracted | 1 study · 242 participants | Very low Downgraded: risk of bias, imprecision |
Rofecoxib compared with naproxen for chronic non‐cancer pain
Population: children and adolescents with chronic non‐cancer pain
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Participant‐reported pain relief of 30% or greater Rofecoxib vs naproxen | no estimate extracted | 1 study · 274 participants | Low Downgraded: risk of bias, imprecision |
Participant‐reported pain relief of 50% or greater Rofecoxib vs naproxen | no estimate extracted | NR | No studies |
Patient Global Impression of Change much or very much improved Rofecoxib vs naproxen | no estimate extracted | NR | No studies |
Any adverse event Rofecoxib vs naproxen | no estimate extracted | 1 study · 274 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse event Rofecoxib vs naproxen | no estimate extracted | 1 study · 310 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse events Rofecoxib vs naproxen | no estimate extracted | 1 study · 310 participants | Very low Downgraded: risk of bias, imprecision |